Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

130.65
-1.6600-1.25%
Post-market: 130.650.00000.00%19:59 EDT
Volume:1.21M
Turnover:158.19M
Market Cap:19.14B
PE:12.92
High:132.49
Open:130.87
Low:130.11
Close:132.31
Loading ...

Jefferies sees Akero, Scholar Rock as ‘promising’ takeover targets

TIPRANKS
·
13 Jun

Biogen Price Target Maintained With a $121.00/Share by Wedbush

Dow Jones
·
12 Jun

Truist Financial Remains a Buy on Biogen (BIIB)

TIPRANKS
·
12 Jun

Analysts Conflicted on These Healthcare Names: Corcept Therapeutics (CORT), Biogen (BIIB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
12 Jun

Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Biogen (BIIB) and Apellis Pharmaceuticals (APLS)

TIPRANKS
·
12 Jun

Biogen’s Hold Rating: Navigating Opportunities and Challenges in Clinical Developments

TIPRANKS
·
12 Jun

Biogen presents additional results from PHOENYCS GO study

TIPRANKS
·
12 Jun

BRIEF-UCB Says Its DZP Shows 'Efficacy' Across Multiple Clinical Endpoints

Reuters
·
12 Jun

Biogen Inc. Announces Promising Phase 3 Trial Results for Dapirolizumab Pegol in Treating Systemic Lupus Erythematosus

Reuters
·
12 Jun

Dapirolizumab Pegol Phase 3 Data in Sle Presented at the Annual European Congress of Rheumatology (Eular) Show Improvement in Fatigue and Reduction in Disease Activity

THOMSON REUTERS
·
12 Jun

Biogen (BIIB) Receives a Buy from TD Cowen

TIPRANKS
·
12 Jun

Biogen’s Strategic Advancements in Autoimmune Sector Drive Buy Rating

TIPRANKS
·
12 Jun

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
12 Jun

Biogen highlights potential of felzartamab

TIPRANKS
·
11 Jun

Biogen Inc. Announces Launch of Phase 3 Trials for Felzartamab in Rare Kidney Diseases, First Results Expected by 2027

Reuters
·
11 Jun

Biogen’s Strategic Growth and Diversification Drive Buy Rating

TIPRANKS
·
11 Jun

Bank of America Securities Reaffirms Their Hold Rating on Biogen (BIIB)

TIPRANKS
·
06 Jun

Biogen Inc. Stock Underperforms Thursday When Compared To Competitors

Dow Jones
·
06 Jun

Biogen Inc. Faces Setback as INESSS Recommends Against Reimbursement for SKYCLARYS™ in Quebec Despite Approval for Friedreich Ataxia Treatment

Reuters
·
05 Jun

Entrada Therapeutics Appoints Dr. Maha Radhakrishnan to Board of Directors Amidst Clinical Advancements in Duchenne Therapies

Reuters
·
03 Jun